Newsroom | 48597 results

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the French medicines safety agency ANSM (Agence nationale de sécurité du médicament et des produits de santé) has authorized the dose-ranging study REVISE, which will investigate the efficacy and...

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella Pertussis, today announced the peer-reviewed publication of Phase 2b trial results in The Lancet Microbe (Link). The published research article summarizes the CHAMPION-1 clinical study of BPZE1, a randomized, double-blind, placebo-controlled study conducted in healthy adults in a controlled human infection model. BP...

SCHAUMBURG, Ill. & PARSIPPANY, N.J.--(BUSINESS WIRE)--The Society of Urologic Oncology (SUO) and Ferring Pharmaceuticals today announced the SUO NMIBC (non-muscle invasive bladder cancer) Fellows Research Grant, created to support outstanding clinical research investigators committed to advancing the understanding and treatment of NMIBC. Two applicants will receive the SUO NMIBC Fellows Research Grant, provided by an educational grant from Ferring Pharmaceuticals. “Advancing research in NMIBC i...

BOSTON--(BUSINESS WIRE)--Instem Unveils New Global Headquarters in Boston, MA Reflecting Customer Obsession, Strategic Growth, and a New Era for Instem...

PITTSBURGH--(BUSINESS WIRE)--CytoAgents announced a poster presentation of new CTO1681 clinical data at the 67th American Society of Hematology Annual Meeting....

MADISON, Wis.--(BUSINESS WIRE)--Archeus Technologies, a company developing multiple differentiated radiopharmaceutical therapies for the treatment of patients with cancer, today announced that it has dosed the first patient in its Phase 1 clinical trial of ART-101 in men with metastatic castration-resistant prostate cancer (mCRPC). ART-101 is a novel receptor-based targeting small molecule developed for the imaging and treatment of prostate cancer. The therapy was invented and developed by Rein...

NEW YORK--(BUSINESS WIRE)--Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced oral drug delivery systems, today announced the publication of a new study in the Journal Pharmaceutics (MDPI) that highlights the effectiveness of its proprietary carbidopa/levodopa formulations (LXM.5) for the treatment of Parkinson's disease. The pharmacokinetic study demonstrated that Laxxon’s novel dosage forms significantly improved bioavailability compared to Sin...

SEATTLE--(BUSINESS WIRE)--AGC Biologics is partnering with ATUM to integrate technology designed to increase yields and shorten the path to clinical trials....

SEATTLE--(BUSINESS WIRE)--Curi Bio is thrilled to announce the close of a $10 Million Series B financing round, led by DreamCIS....

CHICAGO--(BUSINESS WIRE)--At the Radiological Society of North America (RSNA) 2025 Annual Meeting, GE HealthCare (Nasdaq: GEHC) is showcasing several innovations brought to life through an expanded collaboration with NVIDIA. This collaboration underscores GE HealthCare’s ongoing commitment to integrating advanced technologies that aim to transform healthcare delivery and improve patient care. The company is leveraging NVIDIA’s offerings and expertise in areas of physical AI, high performance co...